{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:29:27Z","timestamp":1793734167308,"version":"4.6.1"},"reference-count":68,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) have been shown to promote multiple myeloma (MM) cell growth. We show that the main site of production for BAFF and APRIL is the bone marrow (BM) environment, and that production is mainly by monocytes and neutrophils. In addition, osteoclasts produce very high levels of APRIL, unlike BM stromal cells. Myeloma cells (MMCs) express TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor), the receptor of BAFF\/APRIL, at varying levels. TACI expression is a good indicator of a BAFF-binding receptor. Expression data of purified MMCs from 65 newly diagnosed patients have been generated using Affymetrix microarrays and were analyzed by supervised clustering of groups with higher (TACIhi) versus lower (TACIlo) TACI expression levels. Patients in the TACIlo group had clinical parameters associated with bad prognosis. A set of 659 genes was differentially expressed between TACIhi and TACIlo MMCs. This set makes it possible to efficiently classify TACIhi and TACIlo MMCs in an independent cohort of 40 patients. TACIhi MMCs displayed a mature plasma cell gene signature, indicating dependence on the BM environment. In contrast, the TACIlo group had a gene signature of plasmablasts, suggesting an attenuated dependence on the BM environment. Taken together, our findings suggest using gene expression profiling to identify the group of patients who might benefit most from treatment with BAFF\/APRIL inhibitors.<\/jats:p>","DOI":"10.1182\/blood-2004-11-4512","type":"journal-article","created":{"date-parts":[[2005,4,13]],"date-time":"2005-04-13T05:05:31Z","timestamp":1113368731000},"page":"1021-1030","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":225,"title":["The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature"],"prefix":"10.1182","volume":"106","author":[{"given":"Je\u0301ro\u0302me","family":"Moreaux","sequence":"first","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich W.","family":"Cremer","sequence":"additional","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Reme","sequence":"additional","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Raab","sequence":"additional","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karene","family":"Mahtouk","sequence":"additional","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philine","family":"Kaukel","sequence":"additional","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronique","family":"Pantesco","sequence":"additional","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"De Vos","sequence":"additional","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jourdan","sequence":"additional","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Jauch","sequence":"additional","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Legouffe","sequence":"additional","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Moos","sequence":"additional","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Fiol","sequence":"additional","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"Goldschmidt","sequence":"additional","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Franc\u0327ois","family":"Rossi","sequence":"additional","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hose","sequence":"additional","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Klein","sequence":"additional","affiliation":[{"name":"From INSERM U475 and the Unit for Cellular Therapy, CHU Montpellier, Hopital St Eloi, and the Clinical Hematology Department, CHU Montpellier, Hopital Lapeyronie, Montpellier, France; Medizinische Klinik und Poliklinik V, and the Institut fu\u0308r Humangenetik, Universita\u0308tsklinikum Heidelberg, Heidelberg, Germany; and the Internal Medicine Department B, CHU de Ni\u0302mes, Ni\u0302mes, France."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223403316600_REF1","doi-asserted-by":"crossref","unstructured":"Klein B, Tarte K, Jourdan M, et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol. 2003;78: 106-113.","DOI":"10.1007\/BF02983377"},{"key":"2020021223403316600_REF2","doi-asserted-by":"crossref","unstructured":"Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104: 607-618.","DOI":"10.1182\/blood-2004-01-0037"},{"key":"2020021223403316600_REF3","doi-asserted-by":"crossref","unstructured":"Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. Blood. 2002;99: 2185-2191.","DOI":"10.1182\/blood.V99.6.2185"},{"key":"2020021223403316600_REF4","doi-asserted-by":"crossref","unstructured":"Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res. 2004;64: 1546-1558.","DOI":"10.1158\/0008-5472.CAN-03-2876"},{"key":"2020021223403316600_REF5","doi-asserted-by":"crossref","unstructured":"Hose D, Rossi J-F, Ittrich C, et al. A new molecular classification of multiple myeloma (MM) using gene expression profiling (GEP) and fluorescence in situ hybridisation as predictor for event free survival (EFS). Blood. 2004;104: 25a.","DOI":"10.1182\/blood.V104.11.73.73"},{"key":"2020021223403316600_REF6","doi-asserted-by":"crossref","unstructured":"Bergsagel PL, Kuehl WM. Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma. Immunol Rev. 2003;194: 96-104.","DOI":"10.1034\/j.1600-065X.2003.00052.x"},{"key":"2020021223403316600_REF7","doi-asserted-by":"crossref","unstructured":"Zhan F, Hardin J, Kordsmeier B, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99: 1745-1757.","DOI":"10.1182\/blood.V99.5.1745"},{"key":"2020021223403316600_REF8","doi-asserted-by":"crossref","unstructured":"De Vos J, Thykjaer T, Tarte K, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene. 2002;21: 6848-6857.","DOI":"10.1038\/sj.onc.1205868"},{"key":"2020021223403316600_REF9","doi-asserted-by":"crossref","unstructured":"Tarte K, De Vos J, Thykjaer T, et al. Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. Blood. 2002;100: 1113-1122.","DOI":"10.1182\/blood.V100.4.1113.h81602001113_1113_1122"},{"key":"2020021223403316600_REF10","doi-asserted-by":"crossref","unstructured":"Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med. 2003;349: 2483-2494.","DOI":"10.1056\/NEJMoa030847"},{"key":"2020021223403316600_REF11","doi-asserted-by":"crossref","unstructured":"De Vos J, Couderc G, Tarte K, et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood. 2001;98: 771-780.","DOI":"10.1182\/blood.V98.3.771"},{"key":"2020021223403316600_REF12","doi-asserted-by":"crossref","unstructured":"Wang YD, De Vos J, Jourdan M, et al. Cooperation between heparin-binding EGF-like growth factor and interleukin-6 in promoting the growth of human myeloma cells. Oncogene. 2002;21: 2584-2592.","DOI":"10.1038\/sj.onc.1205355"},{"key":"2020021223403316600_REF13","doi-asserted-by":"crossref","unstructured":"Mahtouk K, Jourdan M, De Vos J, et al. An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis. Blood. 2004;103: 1829-1837.","DOI":"10.1182\/blood-2003-05-1510"},{"key":"2020021223403316600_REF14","doi-asserted-by":"crossref","unstructured":"Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285: 260-263.","DOI":"10.1126\/science.285.5425.260"},{"key":"2020021223403316600_REF15","doi-asserted-by":"crossref","unstructured":"Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189: 1747-1756.","DOI":"10.1084\/jem.189.11.1747"},{"key":"2020021223403316600_REF16","doi-asserted-by":"crossref","unstructured":"Hahne M, Kataoka T, Schroter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med. 1998;188: 1185-1190.","DOI":"10.1084\/jem.188.6.1185"},{"key":"2020021223403316600_","doi-asserted-by":"crossref","unstructured":"Stein JV, Lopez-Fraga M, Elustondo FA, et al. APRIL modulates B and T cell immunity. J Clin Invest. 2002;109: 1587-1598.","DOI":"10.1172\/JCI0215034"},{"key":"2020021223403316600_REF18","doi-asserted-by":"crossref","unstructured":"Mackay F, Schneider P, Rennert P, Browning J. BAFF AND APRIL: a tutorial on B cell survival. Annu Rev Immunol. 2003;21: 231-264.","DOI":"10.1146\/annurev.immunol.21.120601.141152"},{"key":"2020021223403316600_REF19","doi-asserted-by":"crossref","unstructured":"Litinskiy MB, Nardelli B, Hilbert DM, et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol. 2002;3: 822-829.","DOI":"10.1038\/ni829"},{"key":"2020021223403316600_REF20","doi-asserted-by":"crossref","unstructured":"Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2: 465-475.","DOI":"10.1038\/nri844"},{"key":"2020021223403316600_REF21","doi-asserted-by":"crossref","unstructured":"Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004;103: 3148-3157.","DOI":"10.1182\/blood-2003-06-1984"},{"key":"2020021223403316600_REF22","doi-asserted-by":"crossref","unstructured":"Novak AJ, Darce JR, Arendt BK, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2003;103: 689-694.","DOI":"10.1182\/blood-2003-06-2043"},{"key":"2020021223403316600_REF23","doi-asserted-by":"crossref","unstructured":"Zhang XG, Gaillard JP, Robillard N, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood. 1994;83: 3654-3663.","DOI":"10.1182\/blood.V83.12.3654.3654"},{"key":"2020021223403316600_REF24","doi-asserted-by":"crossref","unstructured":"Tarte K, Fiol G, Rossi JF, Klein B. Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro. Leukemia. 2000;14: 2182-2192.","DOI":"10.1038\/sj.leu.2401925"},{"key":"2020021223403316600_REF25","doi-asserted-by":"crossref","unstructured":"Mahtouk K, Hose D, Reme T, et al. Expression of EGF-family receptors and amphiregulin in multiple myeloma: amphiregulin is a growth factor for myeloma cells. Oncogene. 2005;24: 3512-3524.","DOI":"10.1038\/sj.onc.1208536"},{"key":"2020021223403316600_REF26","doi-asserted-by":"crossref","unstructured":"Gu ZJ, Vos JD, Rebouissou C, et al. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia. 2000;14: 188-197.","DOI":"10.1038\/sj.leu.2401632"},{"key":"2020021223403316600_REF27","doi-asserted-by":"crossref","unstructured":"Popp S, Jauch A, Schindler D, et al. A strategy for the characterization of minute chromosome rearrangements using multiple color fluorescence in situ hybridization with chromosome-specific DNA libraries and YAC clones. Hum Genet. 1993;92: 527-532.","DOI":"10.1007\/BF00420933"},{"key":"2020021223403316600_REF28","doi-asserted-by":"crossref","unstructured":"Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998;95: 14863-14868.","DOI":"10.1073\/pnas.95.25.14863"},{"key":"2020021223403316600_REF29","doi-asserted-by":"crossref","unstructured":"Landgrebe J, Wurst W, Welzl G. Permutation-validated principal components analysis of microarray data. Genome Biol. 2002;3: RESEARCH0019.","DOI":"10.1186\/gb-2002-3-4-research0019"},{"key":"2020021223403316600_REF30","doi-asserted-by":"crossref","unstructured":"Craxton A, Magaletti D, Ryan EJ, Clark EA. Macrophage- and dendritic cell-dependent regulation of human B-cell proliferation requires the TNF family ligand BAFF. Blood. 2003;101; 4464-4471.","DOI":"10.1182\/blood-2002-10-3123"},{"key":"2020021223403316600_REF31","doi-asserted-by":"crossref","unstructured":"Gras MP, Laabi Y, Linares-Cruz G, et al. BCMAp: an integral membrane protein in the Golgi apparatus of human mature B lymphocytes. Int Immunol. 1995;7: 1093-1106.","DOI":"10.1093\/intimm\/7.7.1093"},{"key":"2020021223403316600_REF32","doi-asserted-by":"crossref","unstructured":"Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J Jr. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH\/MMSET fusion transcript. Blood. 2003;101: 2374-2376.","DOI":"10.1182\/blood-2002-09-2801"},{"key":"2020021223403316600_REF33","doi-asserted-by":"crossref","unstructured":"Shaughnessy J, Jacobson J, Sawyer J, et al. Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with total therapy I: interpretation in the context of global gene expression. Blood. 2003;101: 3849-3856.","DOI":"10.1182\/blood-2002-09-2873"},{"key":"2020021223403316600_REF34","doi-asserted-by":"crossref","unstructured":"Derksen PW, Keehnen RM, Evers LM, van Oers MH, Spaargaren M, Pals ST. Cell surface proteoglycan syndecan-1 mediates hepatocyte growth factor binding and promotes Met signaling in multiple myeloma. Blood. 2002;99: 1405-1410.","DOI":"10.1182\/blood.V99.4.1405"},{"key":"2020021223403316600_REF35","doi-asserted-by":"crossref","unstructured":"Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood. 1996;87: 1104-1112.","DOI":"10.1182\/blood.V87.3.1104.bloodjournal8731104"},{"key":"2020021223403316600_REF36","doi-asserted-by":"crossref","unstructured":"Yaccoby S, Wezeman MJ, Henderson A, et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res. 2004;64: 2016-2023.","DOI":"10.1158\/0008-5472.CAN-03-1131"},{"key":"2020021223403316600_REF37","doi-asserted-by":"crossref","unstructured":"Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood. 1998;92: 2908-2913.","DOI":"10.1182\/blood.V92.8.2908"},{"key":"2020021223403316600_REF38","doi-asserted-by":"crossref","unstructured":"Yata K, Yaccoby S. The SCID-rab model: a novel in vivo system for primary human myeloma demonstrating growth of CD138-expressing malignant cells. Leukemia. 2004;18: 1891-1897.","DOI":"10.1038\/sj.leu.2403513"},{"key":"2020021223403316600_REF39","doi-asserted-by":"crossref","unstructured":"Klein B, Zhang XG, Jourdan M, et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989;73: 517-526.","DOI":"10.1182\/blood.V73.2.517.517"},{"key":"2020021223403316600_REF40","doi-asserted-by":"crossref","unstructured":"Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas. Nature. 1988;332: 83-85.","DOI":"10.1038\/332083a0"},{"key":"2020021223403316600_REF41","doi-asserted-by":"crossref","unstructured":"Hata H, Xiao H, Petrucci MT, Woodliff J, Chang R, Epstein J. Interleukin-6 gene expression in multiple myeloma: a characteristic of immature tumor cells. Blood. 1993;81: 3357-3364.","DOI":"10.1182\/blood.V81.12.3357.3357"},{"key":"2020021223403316600_REF42","doi-asserted-by":"crossref","unstructured":"Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood. 1995;85: 863-872.","DOI":"10.1182\/blood.V85.4.863.bloodjournal854863"},{"key":"2020021223403316600_REF43","doi-asserted-by":"crossref","unstructured":"O'Connor BP, Raman VS, Erickson LD, et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med. 2004;199: 91-98.","DOI":"10.1084\/jem.20031330"},{"key":"2020021223403316600_REF44","doi-asserted-by":"crossref","unstructured":"Kotenko SV, Izotova LS, Mirochnitchenko OV, et al. Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes. J Biol Chem. 2001;276: 2725-2732.","DOI":"10.1074\/jbc.M007837200"},{"key":"2020021223403316600_REF45","doi-asserted-by":"crossref","unstructured":"Gu ZJ, Costes V, Lu ZY, et al. Interleukin-10 is a growth factor for human myeloma cells by induction of an oncostatin M autocrine loop. Blood. 1996;88: 3972-3986.","DOI":"10.1182\/blood.V88.10.3972.bloodjournal88103972"},{"key":"2020021223403316600_REF46","doi-asserted-by":"crossref","unstructured":"Ardjomand N, Schaffler G, Radner H, ElShabrawi Y. Expression of somatostatin receptors in uveal melanomas. Invest Ophthalmol Vis Sci. 2003;44: 980-987.","DOI":"10.1167\/iovs.02-0481"},{"key":"2020021223403316600_REF47","doi-asserted-by":"crossref","unstructured":"Zatelli MC, Tagliati F, Taylor JE, Rossi R, Culler MD, degli Uberti EC. Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt. J Clin Endocrinol Metab. 2001;86: 2161-2169.","DOI":"10.1210\/jc.86.5.2161"},{"key":"2020021223403316600_REF48","doi-asserted-by":"crossref","unstructured":"Georgii-Hemming P, Stromberg T, Janson ET, Stridsberg M, Wiklund HJ, Nilsson K. The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines. Blood. 1999;93: 1724-1731.","DOI":"10.1182\/blood.V93.5.1724"},{"key":"2020021223403316600_REF49","doi-asserted-by":"crossref","unstructured":"Wagener C, Ergun S. Angiogenic properties of the carcinoembryonic antigen-related cell adhesion molecule 1. Exp Cell Res. 2000;261: 19-24.","DOI":"10.1006\/excr.2000.5038"},{"key":"2020021223403316600_REF50","doi-asserted-by":"crossref","unstructured":"Dodelet VC, Pasquale EB. Eph receptors and ephrin ligands: embryogenesis to tumorigenesis. Oncogene. 2000;19: 5614-5619.","DOI":"10.1038\/sj.onc.1203856"},{"key":"2020021223403316600_REF51","doi-asserted-by":"crossref","unstructured":"Noren NK, Lu M, Freeman AL, Koolpe M, Pasquale EB. Interplay between EphB4 on tumor cells and vascular ephrin-B2 regulates tumor growth. Proc Natl Acad Sci U S A. 2004;101: 5583-5588.","DOI":"10.1073\/pnas.0401381101"},{"key":"2020021223403316600_REF52","doi-asserted-by":"crossref","unstructured":"Li Q, Park PW, Wilson CL, Parks WC. Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury. Cell. 2002;111: 635-646.","DOI":"10.1016\/S0092-8674(02)01079-6"},{"key":"2020021223403316600_REF53","doi-asserted-by":"crossref","unstructured":"Klein B, Li XY, Lu ZY, et al. Activation molecules on human myeloma cells. Curr Top Microbiol Immunol. 1999;246: 335-341.","DOI":"10.1007\/978-3-642-60162-0_41"},{"key":"2020021223403316600_REF54","doi-asserted-by":"crossref","unstructured":"Tarte K, Zhan F, De Vos J, Klein B, Shaughnessy J Jr. Gene expression profiling of plasma cells and plasmablasts: toward a better understanding of the late stages of B-cell differentiation. Blood. 2003;102: 592-600.","DOI":"10.1182\/blood-2002-10-3161"},{"key":"2020021223403316600_REF55","doi-asserted-by":"crossref","unstructured":"Hatzoglou A, Roussel J, Bourgeade MF, et al. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J Immunol. 2000;165: 1322-1330.","DOI":"10.4049\/jimmunol.165.3.1322"},{"key":"2020021223403316600_REF56","doi-asserted-by":"crossref","unstructured":"Negri S, Oberson A, Steinmann M, et al. cDNA cloning and mapping of a novel islet-brain\/JNK-interacting protein. Genomics. 2000;64: 324-330.","DOI":"10.1006\/geno.2000.6129"},{"key":"2020021223403316600_REF57","doi-asserted-by":"crossref","unstructured":"Yasuda J, Whitmarsh AJ, Cavanagh J, Sharma M, Davis RJ. The JIP group of mitogen-activated protein kinase scaffold proteins. Mol Cell Biol. 1999;19: 7245-7254.","DOI":"10.1128\/MCB.19.10.7245"},{"key":"2020021223403316600_REF58","doi-asserted-by":"crossref","unstructured":"Hideshima T, Akiyama M, Hayashi T, et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003;101: 703-705.","DOI":"10.1182\/blood-2002-06-1874"},{"key":"2020021223403316600_REF59","doi-asserted-by":"crossref","unstructured":"Chantry D, Vojtek A, Kashishian A, et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem. 1997;272: 19236-19241.","DOI":"10.1074\/jbc.272.31.19236"},{"key":"2020021223403316600_REF60","doi-asserted-by":"crossref","unstructured":"Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol. 2002;3: 958-965.","DOI":"10.1038\/ni842"},{"key":"2020021223403316600_REF61","doi-asserted-by":"crossref","unstructured":"Draetta G, Piwnica-Worms H, Morrison D, Druker B, Roberts T, Beach D. Human cdc2 protein kinase is a major cell-cycle regulated tyrosine kinase substrate. Nature. 1988;336: 738-744.","DOI":"10.1038\/336738a0"},{"key":"2020021223403316600_REF62","doi-asserted-by":"crossref","unstructured":"Serra M, Reverter-Branchat G, Maurici D, et al. Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol. 2004;15: 151-160.","DOI":"10.1093\/annonc\/mdh004"},{"key":"2020021223403316600_REF63","doi-asserted-by":"crossref","unstructured":"Wang TL, Diaz LA Jr, Romans K, et al. Digital karyotyping identifies thymidylate synthase amplification as a mechanism of resistance to 5-fluorouracil in metastatic colorectal cancer patients. Proc Natl Acad Sci U S A. 2004;101: 3089-3094.","DOI":"10.1073\/pnas.0308716101"},{"key":"2020021223403316600_REF64","doi-asserted-by":"crossref","unstructured":"Silvestris F, Cafforio P, Tucci M, Grinello D, Dammacco F. Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br J Haematol. 2003;122: 39-52.","DOI":"10.1046\/j.1365-2141.2003.04374.x"},{"key":"2020021223403316600_REF65","unstructured":"Hideshima T, Richardson PG, Anderson KC. Targeting proteasome inhibition in hematologic malignancies. Rev Clin Exp Hematol. 2003;7: 191-204."},{"key":"2020021223403316600_REF66","doi-asserted-by":"crossref","unstructured":"Borset M, Seidel C, Hjorth-Hansen H, Waage A, Sundan A. The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Leuk Lymphoma. 1999;32: 249-256.","DOI":"10.3109\/10428199909167385"},{"key":"2020021223403316600_","doi-asserted-by":"crossref","unstructured":"Derksen PW, de Gorter DJ, Meijer HP, et al. The hepatocyte growth factor\/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia. 2003;17: 764-774.","DOI":"10.1038\/sj.leu.2402875"},{"key":"2020021223403316600_REF68","doi-asserted-by":"crossref","unstructured":"Hov H, Holt RU, Ro TB, et al. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells. Clin Cancer Res. 2004;10: 6686-6694.","DOI":"10.1158\/1078-0432.CCR-04-0874"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/3\/1021\/1712064\/zh801505001021.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/3\/1021\/1712064\/zh801505001021.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T20:19:00Z","timestamp":1586204340000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/3\/1021\/21890\/The-level-of-TACI-gene-expression-in-myeloma-cells"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,1]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-11-4512","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,1]]}}}